Aligos Therapeutics (ALGS) Gains from Sales and Divestitures (2019 - 2024)

Aligos Therapeutics has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $4874.0 in Q3 2024.

• For the quarter ending Q3 2024, Gains from Sales and Divestitures changed N/A year-over-year to $4874.0; the trailing twelve-month figure through Sep 2024 stood at $4874.0 (changed N/A YoY), and the FY2022 full-year result was $89054.0, down 72.11% from the prior year.
• Gains from Sales and Divestitures for Q3 2024 stood at $4874.0, up from $2490.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $418776.0 in Q4 2020, with the low at $2490.0 in Q1 2024.
• Historically, Gains from Sales and Divestitures has averaged $134929.4 across 4 years, with a median of $89054.0 in 2022.
• Annual changes were most pronounced in 2021 — Gains from Sales and Divestitures fell 23.74% — and 2022, when it plunged 72.11%.
• Aligos Therapeutics' Gains from Sales and Divestitures stood at $418776.0 in 2020, then declined by 23.74% to $319357.0 in 2021, then sank by 72.11% to $89054.0 in 2022, then slumped by 94.53% to $4874.0 in 2024.
• The last three Gains from Sales and Divestitures figures came in at $4874.0 (Q3 2024), $2490.0 (Q2 2024), and $2490.0 (Q1 2024), per Business Quant data.